- The company is on a growth path due to increased incidence of colorectal cancer.
- Add to this, a windfall from a competitor winding down and revenue growth is accelerating and will accelerate more in H2 and next year.
- This will produce operational leverage and next year a substantial reduction in CapEx, so profit growth is likely to be brisk.
- We don’t think this sound prospect is fully reflected in the share price.
InfuSystem Will Benefit From Tailwinds, But It Is Low On Cash
September 6th, 2019 · No Comments